Cannabis Investors: Ignore This Stock at Your Own Risk

Here is why Charlotte’s Web Holdings (TSX:CWEB) is one of the best stocks to buy in the cannabis market.

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

It may be tempting for investors looking to jump on the marijuana bandwagon to focus on the Canadian pot market. After all, Canada is still the only country in the developed world in which recreational uses of marijuana are legal. Sales of cannabis are projected to grow at an exponential rate in the country, and there are definitely many marijuana companies worth considering.

However, the U.S. market is the largest market in the world, and despite marijuana not yet being legal at the federal level, the CBD market is booming. Let’s see why Charlotte’s Web Holdings (TSX:CWEB), a Colorado-based company, is one of the best ways to cash in on the U.S. market.

One of the biggest players in the US CBD market

By way of a reminder, the Farm Bill that was enacted late last year in the U.S.-made hemp — and hemp-derived CBD — legal at the federal level. Hemp contains negligible amounts of tetrahydrocannabinol (THC), the chemical component in weed that induces the euphoric or “high” feeling in its users.

CBD and CBD-derived products are often lauded for their various medical benefits. These include the positive effects of CBD oil on those suffering of depression and anxiety.

Charlotte’s Web holds a strong market share within the U.S. CBD market. The firm offers various CBD-derived products, including oils, capsules, and topicals, hemp products for dogs, and the company delivers strong sales for every product category. Indeed, Charlotte’s Web holds the largest market share among competitors in this market in the U.S.

Last year, the company produced 675,000 pounds of hemp (about 306,174 kilograms), which is very competitive by industry’s standard. But Charlotte’s Web is projected to produce even more this year. The firm recently announced plans to increase its total hemp acres planted for 2019 to 862, which represents a 187% increase from last year.

In a press release, Deanie Elsner, CEO of Charlotte’s Web said the following: “Interest and demand for our products has been exceptional and growing rapidly. Our 2019 planting strategy ensures we will have the required raw materials to deliver on production targets for Charlotte’s Web products through 2020 and into 2021.”

This rise in demand of CBD products should continue for the foreseeable future. With over 6000 retail locations in the U.S., the firm’s products are sold or shipped in all 50 states of the union.

Financial results

Charlotte’s Web reported its Q1 financial results last month. The company’s USD $21.7 million revenue represented a 66% year over year growth, and its gross profit rose by 53%. While the firm’s earnings before taxes decreased by 27% and its net income decreased by 26%, Charlotte’s Web is managing to do something few of its peers are doing: recording consistent profits.

The company expects revenues to grow at a faster pace than expenses for the rest of the year. With a rise in demand for its products, Charlotte’s Web seems well positioned to keep its earnings rising. 

Should you buy?

The U.S. CBD market will be an even bigger opportunity than the Canadian marijuana market, and Charlotte’s Web is currently the biggest player in this market. The Colorado-based company — which also happens to already be consistently profitable — might just be one of the best ways to benefit from this golden opportunity.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Bakiny has no position in any of the stocks mentioned.  

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »